Department of Internal Medicine, Division of Cardiology, University of Maryland, 110 South Paca Street, 7th Floor, Baltimore, MD 21201, USA.
Department of Internal Medicine, Division of Cardiology, University of Maryland, 110 South Paca Street, 7th Floor, Baltimore, MD 21201, USA.
Heart Fail Clin. 2021 Jul;17(3):357-367. doi: 10.1016/j.hfc.2021.03.005.
Heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD) constitute a high-risk phenotype with significant morbidity and mortality and poor prognosis. Multiple proinflammatory comorbid conditions influence the pathogenesis of HFpEF and CKD. Renal dysfunction in HFpEF is a consequence of the complex interplay between hemodynamic factors, systemic congestion, inflammation, endothelial dysfunction, and neurohormonal mechanisms. In contrast to heart failure with reduced ejection fraction, there is a dearth of effective targeted therapies for HFpEF. Tailoring study design toward the different phenotypes and delving into their pathophysiology may be fruitful in development of effective phenotype-specific targeted pharmaceutical therapies.
射血分数保留的心力衰竭（HFpEF）和慢性肾脏病（CKD）构成了一种具有高发病率、死亡率和预后不良的高危表型。多种促炎合并症影响 HFpEF 和 CKD 的发病机制。HFpEF 中的肾功能障碍是血流动力学因素、全身充血、炎症、内皮功能障碍和神经激素机制之间复杂相互作用的结果。与射血分数降低的心力衰竭不同，HFpEF 缺乏有效的靶向治疗方法。针对不同表型设计研究并深入研究其病理生理学可能有助于开发有效的表型特异性靶向药物治疗。
